Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.

Antoniucci, Diana M; Sellmeyer, Deborah E; Bilezikian, John P; Palermo, Lisa; Ensrud, Kristine E; Greenspan, Susan L; Black, Dennis M

Antoniucci, Diana M; Sellmeyer, Deborah E; Bilezikian, John P; Palermo, Lisa; Ensrud, Kristine E; Greenspan, Susan L; Black, Dennis M.

Affiliation

Antoniucci DM; Division of Endocrinology, Department of Medicine, University of California, San Francisco, California 94107, USA.

J Clin Endocrinol Metab ; 92(3): 942-7, 2007 Mar.

Article in En | MEDLINE | ID: mdl-17164314

Subject(s)

Alendronate/administration & dosage; Calcium/blood; Calcium/urine; Osteoporosis, Postmenopausal/drug therapy; Parathyroid Hormone/administration & dosage; Aged; Alendronate/adverse effects; Algorithms; Bone Density Conservation Agents/administration & dosage; Bone Density Conservation Agents/adverse effects; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypercalcemia/chemically induced; Hypercalciuria/chemically induced; Middle Aged; Osteoporosis, Postmenopausal/blood; Osteoporosis, Postmenopausal/urine; Parathyroid Hormone/adverse effects; Placebos

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parathyroid Hormone / Osteoporosis, Postmenopausal / Calcium / Alendronate Type of study: Clinical_trials Limits: Aged / Female / Humans / Middle aged Language: En Journal: J Clin Endocrinol Metab Year: 2007 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google